Escin — Aescin (Horse Chestnut Triterpene Saponin · CVI · Anti-oedema · High Evidence)

Compound	Escin (Aescin; β-Escin)
Chemical class	Terpenoid — Triterpene Saponin (Triterpenoid saponin mixture; aescigenin glycosides)
CAS	6805-41-0 (escin); 8053-39-2 (β-escin)
Primary source	Aesculus hippocastanum (horse chestnut seeds, 3–6% of dry weight)
Key applications	Chronic venous insufficiency (CVI); anti-oedema; anti-inflammatory; vasoprotective; High RCT evidence
Claim strength	High
Typical form	Horse chestnut seed extract (HCSE) standardised to 16–20% escin; escin isolate (≥95%)
Buy from Herbuno	Horse Chestnut Extract Powder → Horse chestnut Oil Soluble Extract - Aesculus hippocastanum →

Name origin: From Aesculus (horse chestnut genus; Latin aesculus = a type of oak). Escin (also spelled aescin in older literature) is not a single compound but a complex mixture of triterpene saponins — primarily α-escin and β-escin (epimers differing at C-21 ester group configuration), with β-escin being the pharmacologically active form. The aglycone protoaescigenin or barringtogenol C forms the triterpene backbone; multiple sugar chains (glucose, glucuronic acid) and acyl groups (angelic acid, tiglic acid) complete the diverse escin family. Traditional use: Horse chestnut seed preparations have been used in European traditional medicine for centuries — for leg oedema, varicose veins, and haemorrhoids. Systematic evaluation of horse chestnut seed extract (HCSE) for chronic venous insufficiency (CVI) began in the 1970s–1980s and produced one of the strongest evidence bases for any botanical extract in European phytomedicine. Regulatory status: HCSE is licensed as a traditional herbal medicine for CVI in Germany (Commission E monograph), the EU (HMPC assessment), and many European markets. It is among the top-selling botanical medicines in Germany. Commercial source: Horse Chestnut Extract Powder and oil-soluble extract, both standardised to escin content is available from Herbuno.

---

Evidence for Escin Applications

Chronic venous insufficiency (CVI) — High evidence: A Cochrane systematic review (Pittler & Ernst, 2012; 17 RCTs, n=1,083) concluded that HCSE standardised to escin is significantly more effective than placebo for CVI symptoms (leg pain, oedema, pruritus, fatigue) and is comparable to compression stockings in short-term leg volume reduction. The mechanism: escin inhibits lysosomal enzymes (hyaluronidase, elastase) that degrade proteoglycans in capillary walls, reducing vascular permeability and oedema; additionally, escin activates prostaglandin F2α synthesis, promoting venous tone. Claim strength: High.

Anti-oedema and anti-inflammatory: Escin reduces experimentally-induced oedema more potently than most botanicals, via inhibition of NF-κB, COX-2, and lysosomal enzyme release. Clinically, escin has been studied for post-operative oedema reduction (after orthopaedic and urological surgery) with positive results. Claim strength: Moderate (clinical anti-oedema in specific contexts).

Haemorrhoids: HCSE standardised to escin has been studied in haemorrhoidal disease — reducing bleeding, pain, and pruritus in multiple small RCTs. The mechanism (venotonic, anti-oedema) is consistent with CVI mechanism. Claim strength: Moderate.

---

Frequently Asked Questions — Escin

Is horse chestnut the same as edible sweet chestnut?
No — horse chestnut (Aesculus hippocastanum) and sweet chestnut (Castanea sativa) are botanically unrelated despite similar-looking fruit cases. Horse chestnuts (conkers) are toxic raw — escin and related saponins cause nausea, vomiting, and haemolytic effects if raw seeds are eaten. Sweet chestnuts (edible, used in cooking) contain no escin and are safe to eat. This botanical confusion causes occasional poisoning incidents when children or foragers mistake horse chestnut for sweet chestnut.

At what dose is escin effective for CVI?
RCTs showing CVI benefit used HCSE standardised to deliver 50–75 mg β-escin twice daily (total 100–150 mg/day β-escin). At 16–20% escin content, this corresponds to 250–470 mg HCSE twice daily. Delayed-release formulations improve GI tolerability. Onset of clinical benefit: 4–12 weeks of regular use. Maintenance: continued daily use for ongoing benefit — effects plateau then slowly reverse on cessation. HCSE is typically used as a long-term maintenance therapy for CVI, not a short-term course.

Does escin interact with anticoagulants?
Escin has mild anticoagulant activity — reducing platelet aggregation and inhibiting thrombus formation in animal models. Theoretically, escin could potentiate warfarin and other anticoagulants. While published case reports of clinically significant interactions are rare, the theoretical risk warrants standard anticoagulant advisory language in HCSE formulations. The anti-haemostatic risk from escin is lower than from fish oil or high-dose vitamin E but should be disclosed.

Is topical escin effective for bruising?
Yes — topical escin gel (Hirudoid®-type formulations) has been studied for post-traumatic bruising and haematoma resolution. Multiple controlled studies show faster bruising resolution with topical escin versus placebo. The mechanism involves escin’s anti-oedema and vascular permeability-reducing effects at the topical application site. Topical escin does not raise the same GI tolerability concerns as oral HCSE — it is used extensively in European sports medicine for soft tissue injuries.

Related compounds: Boswellic Acid, Ginsenoside Rb1, Lupeol, Escin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery